Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 plus pyrotinib for HER2-positive advanced breast cancer with brain metastases
ChiCTR2300068946Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin and pyrotinib in breast cancer (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoint: Central nervous system objective response rate. Started Mar 2023; status: recruiting.
02
Drugs
disitamab vedotinpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300068946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068946.